RARB
ENSG00000077092
Target class
Nuclear receptor
Chromosome
3
Approved drugs
8
Clinical candidates (approved and in development)
10
- Approved drugs
- 8
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 10
- Chemical probe available
- Yes
- Target name
- RARB
- Gene name
- Retinoic acid receptor beta
- Gene symbol
- RARB
- Protein name
- Retinoic acid receptor beta (RAR-beta) (HBV-activated protein) (Nuclear receptor subfamily 1 group B member 2) (RAR-epsilon)
- HAP
- NR1B2
- RRB2
- RARbeta
- RAR-beta
- Gene biotype
- Protein coding
- Gene family
- Retinoic acid receptors
- Target class
- Nuclear receptor
- Target type
- Human gene
- Tissues expressed in
- 50
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 24.35
- Tissue specificity (Gini)
- 0.437
- Tissue specificity (tau)
- 0.734
- KEGG gene identifiers
- hsa:5915
- Protein interaction confidence
- 0.854944
- Protein interaction partners
- 18
- R-HSA-383280
- R-HSA-5362517
- R-HSA-5617472
- End position
- 25597932
- Start position
- 24687887
- Chromosome
- 3
- Strand
- Forward
- Nucleus . Cytoplasm .
- SUBCELLULAR LOCATION: [Isoform Beta-1]: Nucleus.
- SUBCELLULAR LOCATION: [Isoform Beta-2]: Nucleus.
- SUBCELLULAR LOCATION: [Isoform Beta-4]: Cytoplasm.
- Nucleoplasm
Publication evidence
- PubMed 28167758
- Tissue specificity (tau)
- 0.733935
- Expression inequality (Gini)
- 0.436643
Expression in transcripts per million
- Esophagus - Muscularis
- 24.35
- Uterus
- 15.63
- Cervix - Endocervix
- 15.39
- Prostate
- 15.16
- Nerve - Tibial
- 15.11
Expression in transcripts per million
- Esophagus - Muscularis24.35
- Uterus15.63
- Cervix - Endocervix15.39
- Prostate15.16
- Nerve - Tibial15.11
- Thyroid14.65
- Brain - Nucleus accumbens (basal ganglia)13.54
- Cervix - Ectocervix13.48
- Esophagus - Gastroesophageal Junction13.25
- Pituitary12.69
- Bladder11.64
- Artery - Tibial11.58
- Ovary11.07
- Vagina10.97
- Minor Salivary Gland10.22
- Artery - Coronary9.95
- Colon - Sigmoid9.65
- Brain - Caudate (basal ganglia)9.54
- Fallopian Tube9.18
- Lung9.04
- Brain - Frontal Cortex (BA9)8.34
- Heart - Atrial Appendage7.44
- Kidney - Medulla6.7
- Brain - Putamen (basal ganglia)6.5
- Brain - Cortex6.35
And 29 more, listed on the interactive page.
- GO:0007165
- GO:0048566
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0003677
- GO:0004879
- GO:1990837
regulation of transcription factor activity
- cell-based: ATG_RARb_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
- cell-based: ATG_DR5_RAR_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
- cell-based: ATG_RARb_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
- cell-based: ATG_DR5_RAR_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
Biological samples
- HepG2, cell line
Evidence source
Related records
Trials (564)
- "A Comparative Clinical Evaluation of the Efficacy of Topical Adapalene, Benzoyl Peroxide Gel, Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule, and Their Fixed Combination in Mild to Moderate Acne Vulgaris Patients."
- "AIDA" Protocol (LAP 0493)
- 13-cis Retinoic Acid (Isotretinoin) and Sperm Production
- 13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer
- 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
- 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
- 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
- A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
- A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris
- A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris
- A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- A Clinical Study Evaluating the Efficacy and Safety of Retinoic Acid in Patients With 15q11-q13 Duplication Syndrome
- A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma
- A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel
- A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris
- A Comparative Study of Adapalene Gel,0.3% Versus Tretinoin Emollient Cream, 0.05% for the Treatment of Photoaging
- A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne
- A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis
- A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%
- A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)
Drugs (10)
- Acitretin Retinoid receptor agonist
- Adapalene Retinoic acid receptor agonist
- Alitretinoin Retinoid receptor agonist
- Etretinate Retinoid receptor agonist
- IRX4310 Retinoic acid receptor antagonist
- Isotretinoin Retinoic acid receptor agonist
- Mofarotene Retinoid receptor modulator
- Tamibarotene Retinoic acid receptor beta agonist
- Tazarotene Retinoic acid receptor agonist
- Tretinoin Retinoic acid receptor agonist